Emerging Biomarkers for Immune Checkpoint Inhibitors in Tumors
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".
Deadline for manuscript submissions: closed (20 May 2023) | Viewed by 2452
Special Issue Editors
Interests: cancer immunity and immunotherapy resistance mechanism; autophagy, energy metabolism and carcinogenesis
Interests: tumor diagnostics and therapeutics; cancer immunity
Special Issue Information
Dear Colleagues,
Immune checkpoint inhibitors (ICIs) have recently taken off as promising immuno-therapeutic methods that have slowed down the progress of various cancers and equipped patients with survival advantages. However, the long-term respondents tally is less than 20% of the population. This low response rate warrants the need for biomarkers which can dynamically provide insight into the possible response of patients to ICIs. Biomarkers are biological molecules that predict the pathological state of patients and the potential response they will elicit to ICIs. Predictive biomarkers play a crucial role in analyzing the effects of ICI therapy on patients and potentially filtering out patients who will certainly benefit from ICIs. In this way, resources in immunotherapy can be rationalized better and the healthcare system can administer an alternative mode of treatment to the non-responsive group of patients. Herein, precision therapy can be performed according to the possible responsiveness and needs of patients. Potential biomarkers for cancer immunotherapy, such as PD-1/PD-L1, total mutation burden (TMB), and tumor-infiltrating lymphocytes (TILs), etc., may be used to assist future application of immunotherapy and patient selection in clinical practice.
The aim of this Special Issue is to look into the emerging biomarkers for immune checkpoint inhibitors in tumors. We welcome both original research articles and reviews.
Dr. Honglei Chen
Dr. Hitoshi Dejima
Dr. Min Peng
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biomarkers
- immune checkpoint
- immune checkpoint inhibitors
- immunotherapy
- total mutation burden
- PD-1/PD-L1
- precision therapy
